NCT05117281

Brief Summary

Neuraxial analgesia may improve postoperative outcomes for high-risk children who are susceptible to respiratory complications (e.g. post-operative apnea). The use of spinal anesthesia in infants and children requiring surgeries of the sub-umbilical regions is gaining considerable popularity worldwide. Caudal analgesia along with general anesthesia is a very popular regional technique for prolonged postoperative analgesia in different pediatric surgical procedures where the surgical site is sub-umbilical. Bupivacaine has been thoroughly studied, and a large global experience exists.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2021

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2021

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

November 1, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 11, 2021

Completed
Last Updated

December 2, 2021

Status Verified

November 1, 2021

Enrollment Period

21 days

First QC Date

November 1, 2021

Last Update Submit

November 22, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • FLACC scale FLACC scores will be recorded. FLACC scores will be recorded. FLACC score will be recorded

    Face, Legs, Activity, Cry, Consolability scale will be recorded. Each category is scored on the 0 to 2 scale. Add the scores together (for a total possible score of 0 to 10).

    24 hours postoperative

Secondary Outcomes (1)

  • Total consumption of rescue analgesics

    24 hours

Study Arms (2)

spinal group

ACTIVE COMPARATOR

Plain, isobaric levobupivacaine(0.25%) 0.25 mg/kg

Drug: Levobupivacaine

caudal group

ACTIVE COMPARATOR

Plain, isobaric levobupivacaine (0.25%) 1 ml/kg

Drug: Levobupivacaine

Interventions

Plain, isobaric levobupivacaine (0.25%) 1 ml/kg

Also known as: Levobupivacaine hydrate
caudal group

Eligibility Criteria

Age2 Years - 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age: 2-10 years.
  • Weight: 15-40 kg.
  • Sex: both males and females.
  • ASA physical status: 1-II.
  • Operation: surgery below the umbilicus.

You may not qualify if:

  • Allergic reaction to local anesthetics (LAs).
  • Local or systemic infection (risk of meningitis).
  • Intracranial hypertension.
  • Hydrocephalus.
  • Intracranial hemorrhage.
  • Coagulopathy.
  • Hypovolemia.
  • Parental refusal.
  • Spinal deformities, such as spina bifida or myelomeningocele.
  • Presence of a ventriculoperitoneal shunt because of a risk of shunt infection or dural leak.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut governorate

Asyut, 715715, Egypt

Location

MeSH Terms

Conditions

Pain, PostoperativeAgnosia

Interventions

Levobupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

BupivacaineAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

November 1, 2021

First Posted

November 11, 2021

Study Start

September 10, 2021

Primary Completion

October 1, 2021

Study Completion

October 15, 2021

Last Updated

December 2, 2021

Record last verified: 2021-11

Locations